357 related articles for article (PubMed ID: 26742637)
21. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia.
Grant RJ; Clarke PB
Neuroscience; 2002; 115(4):1281-94. PubMed ID: 12453497
[TBL] [Abstract][Full Text] [Related]
22. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
23. NMDA alters rotenone toxicity in rat substantia nigra zona compacta and ventral tegmental area dopamine neurons.
Munhall AC; Wu YN; Belknap JK; Meshul CK; Johnson SW
Neurotoxicology; 2012 Jun; 33(3):429-35. PubMed ID: 22521663
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
25. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
26. Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.
Elson JL; Kochaj R; Reynolds R; Pienaar IS
Neurotox Res; 2018 Jul; 34(1):16-31. PubMed ID: 29218504
[TBL] [Abstract][Full Text] [Related]
27. The neurokinin-3 receptor (NK3R) antagonist SB222200 prevents the apomorphine-evoked surface but not nuclear NK3R redistribution in dopaminergic neurons of the rat ventral tegmental area.
Hether S; Misono K; Lessard A
Neuroscience; 2013 Sep; 247():12-24. PubMed ID: 23673279
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.
Morales-Garcia JA; Alonso-Gil S; Gil C; Martinez A; Santos A; Perez-Castillo A
Stem Cells Transl Med; 2015 Jun; 4(6):564-75. PubMed ID: 25925836
[TBL] [Abstract][Full Text] [Related]
29. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.
Wąsik A; Romańska I; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
Neurotox Res; 2018 Oct; 34(3):706-716. PubMed ID: 30129004
[TBL] [Abstract][Full Text] [Related]
30. Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.
Chen L; Liu Z; Tian Z; Wang Y; Li S
Stereotact Funct Neurosurg; 2000; 75(2-3):66-75. PubMed ID: 11740172
[TBL] [Abstract][Full Text] [Related]
31. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Winter C; von Rumohr A; Mundt A; Petrus D; Klein J; Lee T; Morgenstern R; Kupsch A; Juckel G
Behav Brain Res; 2007 Dec; 184(2):133-41. PubMed ID: 17698212
[TBL] [Abstract][Full Text] [Related]
32. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
33. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model.
Tripanichkul W; Jaroensuppaperch EO
Int J Neurosci; 2012 May; 122(5):263-70. PubMed ID: 22176529
[TBL] [Abstract][Full Text] [Related]
34. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.
Healy-Stoffel M; Omar Ahmad S; Stanford JA; Levant B
Brain Res; 2014 Jul; 1574():113-9. PubMed ID: 24924804
[TBL] [Abstract][Full Text] [Related]
36. Blockade of Rapid Influx of Extracellular Zn
Tamano H; Morioka H; Nishio R; Takeuchi A; Takeda A
Mol Neurobiol; 2019 Jun; 56(6):4539-4548. PubMed ID: 30341553
[TBL] [Abstract][Full Text] [Related]
37. Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Masilamoni GJ; Groover O; Smith Y
Neurobiol Dis; 2017 Apr; 100():9-18. PubMed ID: 28042095
[TBL] [Abstract][Full Text] [Related]
38. Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain.
Borsini F; Bordi F; Poggi A; Di Matteo V
J Psychopharmacol; 2015 Jul; 29(7):802-11. PubMed ID: 25735994
[TBL] [Abstract][Full Text] [Related]
39. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
Kreiner G; Rafa-Zabłocka K; Barut J; Chmielarz P; Kot M; Bagińska M; Parlato R; Daniel WA; Nalepa I
Sci Rep; 2019 Mar; 9(1):5262. PubMed ID: 30918302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
